Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T cell epitope-containing fragments: candidates for a novel form of specific immunotherapy.

Ítems similars

• Genetic engineering of trimers of hypoallergenic fragments of the major birch pollen allergen, Bet v 1, for allergy vaccination
  per: Vrtala, Susanne, et al.
  Publicat: (2011)
• Random mutagenesis and phage display technology as a tool for identifying ige epitopes of the birch pollen allergen Bet v 1
  per: Guhsl, Elisabeth Eva, et al.
  Publicat: (2014)
• Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy
  per: Linhart, B, et al.
  Publicat: (2014)
• Modulation of the allergic immune response in BALB/c mice by subcutaneous injection of high doses of the dominant T cell epitope from the major birch pollen allergen Bet v 1
  per: BAUER, L, et al.
  Publicat: (1997)
• Effects of adjuvants on the immune response to allergens in a murine model of allergen inhalation: cholera toxin induces a Th1-like response to Bet v 1, the major birch pollen allergen
  per: Wiedermann, U, et al.
  Publicat: (1998)